The Online Investor
Healthcare M&A image Healthcare M&A » By The Online Investor Staff, updated Sat., Aug. 17, 11:47 AM Recent mergers and acquisitions in the Healthcare M&A category.

Slide #100. Novartis CoStim Pharmaceuticals, Inc.

Acquirer: Novartis (NYSE:NVS)
Acquiree: CoStim Pharmaceuticals, Inc.
Details: MPM Capital and Atlas Venture announced today that portfolio company CoStim Pharmaceuticals, Inc. ("CoStim") has been acquired by Novartis for an undisclosed amount. CoStim, founded in 2012 by MPM Managing Director Luke Evnin together with MPM Managing Director-Operations Robert Millman, is an emerging immuno-oncology company developing monoclonal antibody drugs that enable a patient's own immune system to better fight cancer.

Novartis is a multinational healthcare group based in Switzerland. Co. provides healthcare solutions that address the evolving needs of patients and societies worldwide. Co.'s broad portfolio includes innovative medicines, eye care products and cost-saving generic pharmaceuticals. Co.'s operations are organized along three operating divisions: Innovative Medicines Division; Sandoz Division; and Alcon Division. Co.'s operations are supported by the Novartis Institutes for BioMedical Research and Novartis Business Services.

Open the NVS Page at The Online Investor »

Company Name: 
Novartis AG Basel
Website: 
www.novartis.com
Sector: 
Drugs & Pharmaceuticals
Number of ETFs Holding NVS: 
7
Total Market Value Held by ETFs: 
$56.09M
Total Market Capitalization: 
$220.30B
% of Market Cap. Held by ETFs: 
0.03%
 

Open the NVS Page at The Online Investor (in a new window) »

Quotes delayed 20 minutes



Strong Buy (3.50 out of 4)
62nd percentile
(ranked higher than approx. 62% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Healthcare M&A - Slide 100 of 100 Page | www.TheOnlineInvestor.com

Copyright © 1998 - 2019, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.